170 related articles for article (PubMed ID: 38613913)
1. Results from the UNITED study: a multicenter study validating the prognostic effect of the tumor-stroma ratio in colon cancer.
Polack M; Smit MA; van Pelt GW; Roodvoets AGH; Meershoek-Klein Kranenbarg E; Putter H; Gelderblom H; Crobach ASLP; Terpstra V; Petrushevska G; Gašljević G; Kjær-Frifeldt S; de Cuba EMV; Bulkmans NWJ; Vink GR; Al Dieri R; Tollenaar RAEM; van Krieken JHJM; Mesker WE;
ESMO Open; 2024 Apr; 9(4):102988. PubMed ID: 38613913
[TBL] [Abstract][Full Text] [Related]
2. Uniform Noting for International Application of the Tumor-Stroma Ratio as an Easy Diagnostic Tool: Protocol for a Multicenter Prospective Cohort Study.
Smit M; van Pelt G; Roodvoets A; Meershoek-Klein Kranenbarg E; Putter H; Tollenaar R; van Krieken JH; Mesker W
JMIR Res Protoc; 2019 Jun; 8(6):e13464. PubMed ID: 31199317
[TBL] [Abstract][Full Text] [Related]
3. Stromal organization as predictive biomarker for the treatment of colon cancer with adjuvant bevacizumab; a post-hoc analysis of the AVANT trial.
Zunder S; van der Wilk P; Gelderblom H; Dekker T; Mancao C; Kiialainen A; Putter H; Tollenaar R; Mesker W
Cell Oncol (Dordr); 2019 Oct; 42(5):717-725. PubMed ID: 31102145
[TBL] [Abstract][Full Text] [Related]
4. Tumor-stroma ratio predicts recurrence in patients with colon cancer treated with neoadjuvant chemotherapy.
Hansen TF; Kjær-Frifeldt S; Lindebjerg J; Rafaelsen SR; Jensen LH; Jakobsen A; Sørensen FB
Acta Oncol; 2018 Apr; 57(4):528-533. PubMed ID: 28980848
[TBL] [Abstract][Full Text] [Related]
5. Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer.
Zunder SM; van Pelt GW; Gelderblom HJ; Mancao C; Putter H; Tollenaar RA; Mesker WE
Br J Cancer; 2018 Jul; 119(2):164-169. PubMed ID: 29755119
[TBL] [Abstract][Full Text] [Related]
6. A high tumour-stroma ratio (TSR) in colon tumours and its metastatic lymph nodes predicts poor cancer-free survival and chemo resistance.
Strous MTA; Faes TKE; Gubbels ALHM; van der Linden RLA; Mesker WE; Bosscha K; Bronkhorst CM; Janssen-Heijnen MLG; Vogelaar FJ; de Bruïne AP
Clin Transl Oncol; 2022 Jun; 24(6):1047-1058. PubMed ID: 35064453
[TBL] [Abstract][Full Text] [Related]
7. The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial.
Huijbers A; Tollenaar RA; v Pelt GW; Zeestraten EC; Dutton S; McConkey CC; Domingo E; Smit VT; Midgley R; Warren BF; Johnstone EC; Kerr DJ; Mesker WE
Ann Oncol; 2013 Jan; 24(1):179-85. PubMed ID: 22865778
[TBL] [Abstract][Full Text] [Related]
8. The value of additional bevacizumab in patients with high-risk stroma-high colon cancer. A study within the QUASAR2 trial, an open-label randomized phase 3 trial.
Huijbers A; van Pelt GW; Kerr RS; Johnstone EC; Tollenaar RAEM; Kerr DJ; Mesker WE
J Surg Oncol; 2018 Apr; 117(5):1043-1048. PubMed ID: 29448309
[TBL] [Abstract][Full Text] [Related]
9. Computer aided quantification of intratumoral stroma yields an independent prognosticator in rectal cancer.
Geessink OGF; Baidoshvili A; Klaase JM; Ehteshami Bejnordi B; Litjens GJS; van Pelt GW; Mesker WE; Nagtegaal ID; Ciompi F; van der Laak JAWM
Cell Oncol (Dordr); 2019 Jun; 42(3):331-341. PubMed ID: 30825182
[TBL] [Abstract][Full Text] [Related]
10. The tumor-stroma ratio is an independent predictor of survival in patients with 2018 FIGO stage IIIC squamous cell carcinoma of the cervix following primary radical surgery.
Zong L; Zhang Q; Kong Y; Yang F; Zhou Y; Yu S; Wu M; Chen J; Zhang Y; Xiang Y
Gynecol Oncol; 2020 Mar; 156(3):676-681. PubMed ID: 31882242
[TBL] [Abstract][Full Text] [Related]
11. Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project.
Souglakos J; Boukovinas I; Kakolyris S; Xynogalos S; Ziras N; Athanasiadis A; Androulakis N; Christopoulou A; Vaslamatzis M; Ardavanis A; Emmanouilides C; Bompolaki I; Kourousis C; Makrantonakis P; Christofyllakis C; Athanasiadis E; Kentepozidis N; Karampeazis A; Katopodi U; Anagnosopoulos A; Papadopoulos G; Prinarakis E; Kalisperi A; Mavroudis D; Georgoulias V
Ann Oncol; 2019 Aug; 30(8):1304-1310. PubMed ID: 31228203
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of tumour stroma ratio and tumour budding in stage II colon cancer. A nationwide population-based study.
Eriksen AC; Sørensen FB; Lindebjerg J; Hager H; dePont Christensen R; Kjær-Frifeldt S; Hansen TF
Int J Colorectal Dis; 2018 Aug; 33(8):1115-1124. PubMed ID: 29785462
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of the tumor-stroma ratio in squamous cell lung cancer, a cohort study.
Smit MA; Philipsen MW; Postmus PE; Putter H; Tollenaar RA; Cohen D; Mesker WE
Cancer Treat Res Commun; 2020; 25():100247. PubMed ID: 33249210
[TBL] [Abstract][Full Text] [Related]
15. Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer.
Mlecnik B; Bifulco C; Bindea G; Marliot F; Lugli A; Lee JJ; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Börger E; Hartmann A; Geppert C; Kolwelter J; Merkel S; Grützmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Léonard D; Remue C; Wang JY; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson EK; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Fredriksen T; Buttard B; Lafontaine L; Bruni D; Lanzi A; El Sissy C; Haicheur N; Kirilovsky A; Berger A; Lagorce C; Paustian C; Ballesteros-Merino C; Dijkstra J; van de Water C; van Lent-van Vliet S; Knijn N; Muşină AM; Scripcariu DV; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Torigoe T; Sato N; Furuhata T; Takemasa I; Itoh K; Patel PS; Vora HH; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Kawakami Y; Marincola FM; Ascierto PA; Fox BA; Pagès F; Galon J
J Clin Oncol; 2020 Nov; 38(31):3638-3651. PubMed ID: 32897827
[TBL] [Abstract][Full Text] [Related]
16. Prognostic evaluation of tumor-stroma ratio in patients with early stage cervical adenocarcinoma treated by surgery.
Pongsuvareeyakul T; Khunamornpong S; Settakorn J; Sukpan K; Suprasert P; Intaraphet S; Siriaunkgul S
Asian Pac J Cancer Prev; 2015; 16(10):4363-8. PubMed ID: 26028100
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of tumor-stroma ratio in tumor-positive axillary lymph nodes of breast cancer patients.
Vangangelt KMH; Tollenaar LSA; van Pelt GW; de Kruijf EM; Dekker TJA; Kuppen PJK; Tollenaar RAEM; Mesker WE
Int J Cancer; 2018 Dec; 143(12):3194-3200. PubMed ID: 29978463
[TBL] [Abstract][Full Text] [Related]
18. Association between tumor-stroma ratio and prognosis in solid tumor patients: a systematic review and meta-analysis.
Wu J; Liang C; Chen M; Su W
Oncotarget; 2016 Oct; 7(42):68954-68965. PubMed ID: 27661111
[TBL] [Abstract][Full Text] [Related]
19. Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.
Chibaudel B; Henriques J; Rakez M; Brenner B; Kim TW; Martinez-Villacampa M; Gallego-Plazas J; Cervantes A; Shim K; Jonker D; Guerin-Meyer V; Mineur L; Banzi C; Dewdney A; Dejthevaporn T; Bloemendal HJ; Roth A; Moehler M; Aranda E; Van Cutsem E; Tabernero J; Schmoll HJ; Hoff PM; André T; de Gramont A
JAMA Netw Open; 2020 Oct; 3(10):e2020425. PubMed ID: 33074326
[TBL] [Abstract][Full Text] [Related]
20. Tumour stroma ratio is a potential predictor for 5-year disease-free survival in breast cancer.
Yan D; Ju X; Luo B; Guan F; He H; Yan H; Yuan J
BMC Cancer; 2022 Oct; 22(1):1082. PubMed ID: 36271354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
